Postexposure Efficacy of Recombinant Vesicular Stomatitis Virus Vectors Against High and Low Doses of Marburg Virus Variant Angola in Nonhuman Primates

A recombinant vesicular stomatitis virus (rVSV) expressing the Marburg virus (MARV) Musoke variant glycoprotein fully protects macaques against 2 MARV variants and Ravn virus as a preventive vaccine and MARV variant Musoke as a postexposure treatment. To evaluate postexposure efficacy against the mo...

Descripción completa

Detalles Bibliográficos
Autores principales: Woolsey, Courtney, Geisbert, Joan B, Matassov, Demetrius, Agans, Krystle N, Borisevich, Viktoriya, Cross, Robert W, Deer, Daniel J, Fenton, Karla A, Eldridge, John H, Mire, Chad E, Geisbert, Thomas W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Supplement Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6249565/
https://www.ncbi.nlm.nih.gov/pubmed/29939296
http://dx.doi.org/10.1093/infdis/jiy293
_version_ 1783372778392518656
author Woolsey, Courtney
Geisbert, Joan B
Matassov, Demetrius
Agans, Krystle N
Borisevich, Viktoriya
Cross, Robert W
Deer, Daniel J
Fenton, Karla A
Eldridge, John H
Mire, Chad E
Geisbert, Thomas W
author_facet Woolsey, Courtney
Geisbert, Joan B
Matassov, Demetrius
Agans, Krystle N
Borisevich, Viktoriya
Cross, Robert W
Deer, Daniel J
Fenton, Karla A
Eldridge, John H
Mire, Chad E
Geisbert, Thomas W
author_sort Woolsey, Courtney
collection PubMed
description A recombinant vesicular stomatitis virus (rVSV) expressing the Marburg virus (MARV) Musoke variant glycoprotein fully protects macaques against 2 MARV variants and Ravn virus as a preventive vaccine and MARV variant Musoke as a postexposure treatment. To evaluate postexposure efficacy against the most pathogenic MARV variant, Angola, we engineered rVSVs expressing homologous Angola glycoprotein. Macaques were challenged with high or low doses of variant Angola and treated 20–30 minutes after exposure. A total of 25% and 60%–75% of treated macaques survived the high-dose and low-dose challenges, respectively. The more rapid disease progression of variant Angola versus variant Musoke may account for the incomplete protection observed.
format Online
Article
Text
id pubmed-6249565
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-62495652018-11-27 Postexposure Efficacy of Recombinant Vesicular Stomatitis Virus Vectors Against High and Low Doses of Marburg Virus Variant Angola in Nonhuman Primates Woolsey, Courtney Geisbert, Joan B Matassov, Demetrius Agans, Krystle N Borisevich, Viktoriya Cross, Robert W Deer, Daniel J Fenton, Karla A Eldridge, John H Mire, Chad E Geisbert, Thomas W J Infect Dis Supplement Articles A recombinant vesicular stomatitis virus (rVSV) expressing the Marburg virus (MARV) Musoke variant glycoprotein fully protects macaques against 2 MARV variants and Ravn virus as a preventive vaccine and MARV variant Musoke as a postexposure treatment. To evaluate postexposure efficacy against the most pathogenic MARV variant, Angola, we engineered rVSVs expressing homologous Angola glycoprotein. Macaques were challenged with high or low doses of variant Angola and treated 20–30 minutes after exposure. A total of 25% and 60%–75% of treated macaques survived the high-dose and low-dose challenges, respectively. The more rapid disease progression of variant Angola versus variant Musoke may account for the incomplete protection observed. Oxford University Press 2018-12-15 2018-06-25 /pmc/articles/PMC6249565/ /pubmed/29939296 http://dx.doi.org/10.1093/infdis/jiy293 Text en © The Author(s) 2018. Published by Oxford University Press for the Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Supplement Articles
Woolsey, Courtney
Geisbert, Joan B
Matassov, Demetrius
Agans, Krystle N
Borisevich, Viktoriya
Cross, Robert W
Deer, Daniel J
Fenton, Karla A
Eldridge, John H
Mire, Chad E
Geisbert, Thomas W
Postexposure Efficacy of Recombinant Vesicular Stomatitis Virus Vectors Against High and Low Doses of Marburg Virus Variant Angola in Nonhuman Primates
title Postexposure Efficacy of Recombinant Vesicular Stomatitis Virus Vectors Against High and Low Doses of Marburg Virus Variant Angola in Nonhuman Primates
title_full Postexposure Efficacy of Recombinant Vesicular Stomatitis Virus Vectors Against High and Low Doses of Marburg Virus Variant Angola in Nonhuman Primates
title_fullStr Postexposure Efficacy of Recombinant Vesicular Stomatitis Virus Vectors Against High and Low Doses of Marburg Virus Variant Angola in Nonhuman Primates
title_full_unstemmed Postexposure Efficacy of Recombinant Vesicular Stomatitis Virus Vectors Against High and Low Doses of Marburg Virus Variant Angola in Nonhuman Primates
title_short Postexposure Efficacy of Recombinant Vesicular Stomatitis Virus Vectors Against High and Low Doses of Marburg Virus Variant Angola in Nonhuman Primates
title_sort postexposure efficacy of recombinant vesicular stomatitis virus vectors against high and low doses of marburg virus variant angola in nonhuman primates
topic Supplement Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6249565/
https://www.ncbi.nlm.nih.gov/pubmed/29939296
http://dx.doi.org/10.1093/infdis/jiy293
work_keys_str_mv AT woolseycourtney postexposureefficacyofrecombinantvesicularstomatitisvirusvectorsagainsthighandlowdosesofmarburgvirusvariantangolainnonhumanprimates
AT geisbertjoanb postexposureefficacyofrecombinantvesicularstomatitisvirusvectorsagainsthighandlowdosesofmarburgvirusvariantangolainnonhumanprimates
AT matassovdemetrius postexposureefficacyofrecombinantvesicularstomatitisvirusvectorsagainsthighandlowdosesofmarburgvirusvariantangolainnonhumanprimates
AT aganskrystlen postexposureefficacyofrecombinantvesicularstomatitisvirusvectorsagainsthighandlowdosesofmarburgvirusvariantangolainnonhumanprimates
AT borisevichviktoriya postexposureefficacyofrecombinantvesicularstomatitisvirusvectorsagainsthighandlowdosesofmarburgvirusvariantangolainnonhumanprimates
AT crossrobertw postexposureefficacyofrecombinantvesicularstomatitisvirusvectorsagainsthighandlowdosesofmarburgvirusvariantangolainnonhumanprimates
AT deerdanielj postexposureefficacyofrecombinantvesicularstomatitisvirusvectorsagainsthighandlowdosesofmarburgvirusvariantangolainnonhumanprimates
AT fentonkarlaa postexposureefficacyofrecombinantvesicularstomatitisvirusvectorsagainsthighandlowdosesofmarburgvirusvariantangolainnonhumanprimates
AT eldridgejohnh postexposureefficacyofrecombinantvesicularstomatitisvirusvectorsagainsthighandlowdosesofmarburgvirusvariantangolainnonhumanprimates
AT mirechade postexposureefficacyofrecombinantvesicularstomatitisvirusvectorsagainsthighandlowdosesofmarburgvirusvariantangolainnonhumanprimates
AT geisbertthomasw postexposureefficacyofrecombinantvesicularstomatitisvirusvectorsagainsthighandlowdosesofmarburgvirusvariantangolainnonhumanprimates

Ejemplares similares